---
schema_version: "secwatch.filing_event.v1"
accession: "0001867096-26-000055"
form_type: "8-K"
ticker: "XERS"
cik: "0001867096"
company_name: "Xeris Biopharma Holdings, Inc."
filed_at: "2026-07-17T20:20:39+00:00"
generated_at: "2026-07-17T20:22:14.000756+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Xeris retires $33.5M of 2028 convertible notes via exchange and conversion

## Summary
- Exchanged ~$23M principal of 8.00% Convertible Senior Notes due 2028 for ~5.0M shares and ~$23M cash.
- Separately, a holder converted $10.5M principal into ~3.6M shares.
- After transactions, no 2028 Notes remain outstanding; all cancelled.
- Shares issued in exchange were unregistered, relying on Section 4(a)(2) exemption; conversion shares on Section 3(a)(9).
- Company funded cash portion with liquidity on-hand.

## SEC filing metadata
- accession: 0001867096-26-000055
- form_type: 8-K
- ticker: XERS
- cik: 0001867096
- company_name: Xeris Biopharma Holdings, Inc.
- filed_at: 2026-07-17T20:20:39+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 3.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867096/000186709626000055/0001867096-26-000055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867096/000186709626000055/xers-20260715.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001867096-26-000055
- JSON: https://secwatch.observer/filing/0001867096-26-000055.json
- Plain text: https://secwatch.observer/filing/0001867096-26-000055.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.